Cinclus Pharma (CINPHA) KOL Event summary

Introduction and agenda

• The event focused on linaprazan glurate, a next-generation PCAB, and its potential in addressing unmet needs in GERD, especially severe erosive GERD.

• The agenda included a KOL-led overview of GERD, limitations of current therapies, real-world patient cases, and a commercial landscape discussion.

KOL background and credentials

• Dr. Prateek Sharma, Professor of Medicine, is internationally recognized for his work in GI diseases and cancer.

• He has over 550 publications, including guidelines and major textbooks, and is a frequent speaker at scientific meetings.

Market insights and analysis

• GERD affects about 20% of the U.S. population and 14% globally, with significant impact on quality of life and productivity.

• Erosive GERD, especially grades C and D, represents a large, underserved market of about 10 million patients in the USA and Europe.

• The market is dynamic, with frequent drug switching due to high relapse rates and persistent symptoms.